DT&I, one of the fastest growing venture capital firm in Korea, invests in early and growth stages of firms that have the potential to grow rapidly into successful businesses. We back innovative businesses that focus on broader industry initiatives in the areas of consumer, mobile, digital contents, healthcare & biotech.
DT&I manages $250 million in committed capital primarily through nine funds and has invested more than 90+ companies since 2015. Investors include major corporations, financial institutions and soveriegn wealth funds.
Our investment team has 8 decades of combined venture capital, investment banking, corporate and operating experiences that allows us partner with talented entrepreneurs and help them grow and develop, especially in the early stages.
DT&I manages $250 million in committed capital primarily through nine funds and has invested more than 90+ companies since 2015. Investors include major corporations, financial institutions and soveriegn wealth funds.
Our investment team has 8 decades of combined venture capital, investment banking, corporate and operating experiences that allows us partner with talented entrepreneurs and help them grow and develop, especially in the early stages.
Employees: 11-50
Founded date: 2015
Investment Type: Venture Capital
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 03.08.2026 | Just a mom... | inocras.com | $31M | United Sta... |
Mentions in press and media 3
| Date | Title | Description |
| 05.08.2026 | Inocras Fuels U.S. Precision Oncology Push with $31M Capital Infusion | Inocras, a San Diego bioinformatics leader, secured $31M in Series B-3 financing, raising its total capital to $100M. This investment fuels rapid U.S. expansion of its CLIA/CAP-certified whole-genome sequencing (WGS) and automated analytics... |
| 03.08.2026 | Inocras Closes $31M Series B-3 Financing | Inocras Inc., a San Diego, CA-based bioinformatics-led company leveraging whole-genome data and proprietary analytics to deliver curated insights, raised $31m in Series B-3 financing. Backers included NDS Corporation, Aimed Bio, IMM Investm... |
| 03.08.2026 | Inocras Closes $31M for Whole-Genome Bioinformatics Platform | What You Should Know San Diego-based bioinformatics company Inocras Inc. closed an oversubscribed $31M Series B-3 financing round, bringing its total capital raised to approximately $100M. The funding round was supported by strategic invest... |